Abstract

DEVELOPMENT AND EVALUATION OF SOLID LIPID NANOPARTICLES OF SERTRALINE HCL

Ajay Kumar K.B., S.T. Bhagawati*, Manjunath K., Sreevathsa E.R., Mancy S.P.

ABSTRACT

Antidepressants are a type of medicine used to treat clinical depression, obsessive-compulsive disorder (OCD) etc. Sertraline HCl is a serotonin reuptake inhibitor anti-depressant with poor bioavailability and aqueous solubility. The aim of the present study was to design Sertraline HCl solid lipid Nano-particles and to evaluate them. The sertraline HCl loaded solid lipid nanoparticles were prepared by using the different lipids like Tristearin, GMS and Compritol with tween 80 and Poloxamer as a surfactants in combination with soy lecithin as a stabilizer by hot melt homogenization followed by ultra-sonication method. FTIR and DSC studies confirmed that there was no interaction between the drug and lipids used. The prepared sertraline SLNs are characterized for particle size, zeta potential, polydispersity index, entrapment efficiency, drug content and invitro drug release. The particle size of Sertraline HCl SLNs ranged from 35.88 to 158.24 nm. The PDI of all formulations were good within the range of 0.136 to 0.600. The zeta potential of drug loaded SLN with lipids (TS, GMS & CM) showed zeta potential ranged from -20.5 to -26.6 mV. Entrapment efficiency of all formulations were in the range of 78.68 to 95.23 %. The Cumulative percentage release of optimized formulation (F2) showed good release after 24 hr (89.58 %). The percentage release kinetic studies showed that the release was first order diffusion controlled and the n value (0.46) obtained from the Korsmeyer-Peppas model indicated the release mechanism was Quasi-Fickian type.

Keywords: Sertraline HCl, Solid Lipid Nanoparticles, FTIR, DSC, in vitro drug release.